Sentences with phrase «in generic drug prices»

Profit declines sharply and company cuts full - year outlook

Cardinal Health Inc. reported a sharp decline in profit in its last quarter and lowered its full - year outlook following inventory write - downs in its overseas businesses and a sharper - than - anticipated decline in generic drug prices.

The U.S. filed its first charges in a generic drug price - fixing probe on Wednesday, according to a report.

Not exact matches

Mylan No. 2 targeted in massive generic drug price collusion probe.

Rajiv Malik, president and executive director at EpiPen maker Mylan (essentially the company's number two exec), has been named in a wide - ranging civil suit alleging drug price collusion by numerous prominent generic drug makers.

Walgreens had forecast that the prices of generic drugs would fall — only to realize that in fact they were rising.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

Teva said in a statement it would soon start producing a generic version of the drug that will be «priced significantly lower than Viagra,» which will result in «millions in savings to consumers» and «make this medication accessible to people who might otherwise not have been able to afford it.»

Plus, a handful of companies will typically all get approved to make a generic at once, which ideally creates competition in the marketplace and can sometimes result in even lower prices for those drugs.

Nothing about the drug has changed in that time, and the fact that it's generic flies in the face of the argument that lack of generic competition is the reason for drastic price hikes.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since biosimilars are so new to the U.S. market (there have been just five total approved here since 2015), it's been hard to gauge whether or not they can make a formidable dent in high drug prices by offering generic alternatives to branded treatments.

The whole industry faces turmoil with the advent of laws in several provinces demanding lower prices on generic drugs.

In Ontario, where the drug reforms began, reimbursements for all generics are down to 25 % of the branded price.

Acquiring Akorn would add around $ 1 billion in annual sales to Fresenius» drugmaking division, giving it a significantly larger presence in eyecare and other areas widely perceived as somewhat insulated from generic drug pricing pressure.

Teva beats first - quarter expectations but still has the same old problems Copaxone's market share and new generic launches helped Teva to forecast - beating profit and revenue but problems persistTeva had to make pricing concessions on its flagship multiple sclerosis drug Copaxone, and now expects a delay in approval of a key migraine drug, fremanezumab.

In the U.S. some generic drugs have an inflated price because they are monopolized by one company.

«A civil war has broken out among the most powerful players in the pharmaceutical industry — including brand - name and generic drug makers, and even your local pharmacists — with each blaming others for the rising price of medicine.»

Prices for some generic drugs have increased in recent years, adversely affecting patients who rely on them.

Decreased market competition causes generic drug prices to rise significantly, according to an article published in Annals of Internal Medicine.

In addition, researchers found low market competition levels had a more pronounced correlation with drug prices in lower - priced generic drugs compared with their higher - priced counterpartIn addition, researchers found low market competition levels had a more pronounced correlation with drug prices in lower - priced generic drugs compared with their higher - priced counterpartin lower - priced generic drugs compared with their higher - priced counterparts.

After controlling for other factors, a generic drug in the highest marketing competition group was expected to see a decrease of 32 percent in price over the study period, while a generic drug in the lowest market competition was expected to see a price increase of 47 percent over the same period.

These include patent expirations, the rise of competition from generics, a downward pressure on drug prices, increasing scrutiny from regulators and health technology assessment bodies, pressure to move research offshore, and the crisis in R&D productivity.

If they are on the market without generic versions to challenge them then companies can maintain monopoly prices, and in doing so harm consumers by preventing or delaying access to cheaper drugs.»

Researchers found that increasing the use of generic drugs and bringing Canadian drug prices in line with other countries where universal drug plans achieve better prices through bulk purchasing and negotiation, would add up to significant savings.

As it has for its HIV drugs, Gilead plans to provide patient assistance within the U.S., to license the drug (for a fee) to select generic manufacturers outside the U.S., and to lower prices in low - and middle - income countries.

However, because the gains which have been made in reducing health care spending are largely attributable to price dynamics (such as reduced or no growth in physician reimbursement rates, and high use of cheaper generic drugs), the authors warn that any future economic recovery might reverse the progress that has been made in recent years.

Although generic ARV prices have plummeted to as little as $ 100 per person for a year's treatment, the report also notes that when people develop drug - resistant viruses and need «second - line treatments,» it's much more expensive; in high - income countries, the cost can run up to $ 6000 per month.

In spite of all the efforts to raise awareness and address the problem of fake drugs, a major complication remains: Generic drugs, as well as branded drugs, are often produced overseas and many are sold online, which saves cost and can bring the price of medication down, making it affordable to many people.

And because generics are available only for drugs whose patent has run out, the competition in the marketplace among manufacturers drives the price down.

We were originally attracted to TEVA because of its leading position in generic drugs, its free cash flow generation from its branded drug division, its recent dividend growth, and its cheap price to our estimation of its intrinsic value.

Generic drugs are very cheap in Thailand but unless you already have an idea of how much you should be paying, you will be charged double or triple the real price.

Dr. Hill's work has included serving as trial counsel for plaintiffs and defendants in patent infringement suits involving breast and ovarian cancer gene tests, radiology informatics, hospital information systems, orthopedic surgical devices, MRI diffusion tensor imaging, generic drugs in Hatch - Waxman patent litigation, and biologics in suits brought under the Biologics Price Competition and Innovation Act.

Currently represents a U.S. company in the Department of Justice's criminal investigation of price fixing of generic drugs

[11] In order to stop this inflationary effect on generic drug prices, in 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebateIn order to stop this inflationary effect on generic drug prices, in 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebadrug prices, in 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebatein 2006, the Ontario Drug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebaDrug Benefit Act, the Drug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebaDrug Interchangeability and Dispensing Fee Act, and the Regulations under them were amended to prohibit rebates.

[10] Prior to 2006, the price at which manufacturers could apply to list generic drugs in the Formulary was capped by regulations under the Actsat effectively 63 % of the price of the brand - name drug.

In such patients, low priced generic risk pills that combine aspirin with a statin drug in order to reduce cholesterol and lower blood pressure can bring down the chances of suffering another stroke or even dying by two - thirdIn such patients, low priced generic risk pills that combine aspirin with a statin drug in order to reduce cholesterol and lower blood pressure can bring down the chances of suffering another stroke or even dying by two - thirdin order to reduce cholesterol and lower blood pressure can bring down the chances of suffering another stroke or even dying by two - thirds.

The reforms follow an agreement with the generic medicines sector and an in - principle agreement with the proprietary medicines sector and the Government said they would see a 50 % drop in prices for common drugs.